Navigation Links
MIODx Licenses Key Immunotherapy Technologies from UCSF
Date:2/23/2017

SAN JOSE, Calif., Feb. 23, 2017 /PRNewswire/ -- MIODx announced today that it has signed an exclusive license for two key immunotherapy technologies from the University of California, San Francisco (UCSF).  The first technology provides a method to monitor a patient for response to immune checkpoint inhibitor therapy such as PD-L1 and CTLA-4.  The second license extends the technology with a method to detect if a patient is likely to have an immune-related adverse event (IRAE) from their immunotherapy regimen.

"Diagnostic assays that help guide immunotherapies represent a huge unmet clinical need," said Lawrence Fong, MD, a science advisor to MIODx and leader of the Cancer Immunotherapy Program at the Helen Diller Family Comprehensive Cancer Center at UCSF. "Rather than treating all patients, we need to select patients who can respond to these treatments as well as determine which patients may develop side effects." 

Immunotherapies have shown tremendous gains in the treatment of certain cancers.  The field of cancer immunotherapies has exploded with hundreds of drugs currently in clinical trials or in development. 

"While we are very excited by what we see in terms of the effect these drugs have on certain patient populations, we believe that there remains a critical need to monitor patients, as there is still a huge unknown on what is happening to their immune system," said MIODx CEO M. Allen Northrup, PhD, FRSC.

This partnership was facilitated by the UCSF Office of Technology Management (OTM), which coordinates UCSF's efforts in forging collaborations and licensing technologies that translate cutting-edge science on campus into products and therapies that directly benefit people worldwide.

MIODx also announced that they have entered into an agreement with UCSF to provide immunosequencing services as part of the validation and commercialization of the technology. 

"We plan on having two paths forward for the immunosequencing platform," said Sean Givens, the company's COO.   "As a research service for pharma and academics working on checkpoint inhibitor therapies, and as a doctor-ordered test for oncologists to monitor their patients that are undergoing immunotherapy."

MIODx has already begun working with collaborators and expects to launch the research service in Q2 2017.

About MIODx

MIODx is a privately held company leading the discovery of early detection and prognostic cancer biomarkers through the company's proprietary platforms. The company's VerifyDx™ platform utilizes a highly sensitive, multiplex PCR assay and advanced bioinformatics to interrogate multiple DNA and RNA pathways that are implicated in highly metastatic cancer. In addition to the VerifyDx™ platform, MIODx utilizes high throughput immune sequencing to generate information on T and B cell diversity that is being applied to monitoring a patient's response to immunotherapy.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/miodx-licenses-key-immunotherapy-technologies-from-ucsf-300412111.html


'/>"/>
SOURCE MIODx
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Jill Hagenkord MD Joins MIODx Board of Directors
2. Teewinot Life Sciences Corporation Licenses Biosynthetic Technology to AMRI for the Production and Sale of the First Commercially Available CBCA Analytical Standard
3. PogoTec™ Licenses WiTricity® Technology to Enable Wireless Energy Transfer for Electronic Devices Associated with Eyewear
4. Brain Sentry Licenses Breakthrough Wearable Sensor Technology from Johns Hopkins University
5. Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up
6. Neogen licenses Cargill patents
7. FDA, EMA Extend Licenses for Aptiv Solutions ADDPLAN® Software for Clinical Trials
8. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
9. Sigma Life Science Licenses CompoZr Zinc Finger Nuclease Technology to Horizon Discovery
10. Genomatica Licenses TeselaGen Software for DNA Design
11. Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... ... Vice President of Clinical Operations. She brings years of expertise in establishing and ... her professional foundation as a licensed occupational therapist, through a variety of leadership ...
(Date:5/22/2017)... ... , ... Stratevi, a boutique firm that partners with healthcare companies to creatively ... office in downtown Boston at 745 Atlantic Ave. , “We are seeing that ... on the value they provide, not just to patients, but also payers. Having a ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... the lengthy trial and error process by finding the right antidepressant faster. ... strengthen the doctor-patient relationship through a personalized approach to treatment. , ...
(Date:5/18/2017)... ... May 18, 2017 , ... ... Tapas Cooking Challenge is a two-hour team-building package designed for groups of 10-30 ... Chef Jodi Abel, which include items, such as Blackened Shrimp with Edamame Salad, ...
Breaking Biology Technology:
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):